期刊文献+

群体模型分析方法评估基因多态性对药物PK/PD的影响

Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
下载PDF
导出
摘要 多态性(polymorphism)是指在一个生物群体中,同时和经常存在两种或多种不连续的变异型或基因型(genotype)或等位基因(allele),亦称遗传多态性或基因多态性(gene polymorphism)。这种基因多态性可能对药物的药动学和药效学产生一定程度的影响。基因组学的研究对实现个性化、以患者为导向的精准医学治疗方式具有重要作用。群体模型分析是采用模型化的方法来定量描述药动学及药效学参数与个体特征之间的相关性和变异性,可以量化协变量产生的影响。目前这一方法已被广泛应用。本文系统地介绍采用群体模型方法评估基因多态性对药物PK/PD影响的应用实例。 Polymorphism refers to the simultaneous and frequent existence of two or more discontinuous variants or genotypes or alleles in a biological population,also known as genetic polymorphisms or genes Polymorphism.This gene polymorphism may have a certain degree of influence on the pharmacokinetics and pharmacodynamics of the drug.The study of genomics plays an important role in realizing personalized,patient-oriented precision medicine treatment.Population model analysis is to use a modeling method to quantitatively describe the correlation and variability between pharmacokinetic and pharmacodynamic parameters and individual characteristics and to quantify the impact of covariates.At present,this method has been widely used.This paper systematically introduces the application examples of using the population model approach to assess the effects of genetic polymorphisms on the drug PK/PD.
作者 刘璐 石雨菲 何庆烽 徐凤艳 王鲲 蔡卫民 相小强 LIU Lu;SHI Yufei;HE Qingfeng;XU Fengyan;WANG Kun;CAI Weimin;XIANG Xiaoqiang(Department of Clinical Pharmacy,School of Pharmacy,Fudan University,Shanghai 200032,China;Shanghai Qiangshi Information Technology Co.,Ltd,Shanghai 200032,China)
出处 《中国临床药理学与治疗学》 CAS CSCD 2023年第11期1275-1282,共8页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金项目(81973389,82011540409)。
关键词 定量药理学 基因多态性 群体药动学 quantitative pharmacology genetic polymorphism population pharmacokinetics
  • 相关文献

参考文献7

二级参考文献96

  • 1Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5215
  • 3Conzalez F, Idle JR. Pharmacogenietic phenotyping and genotyping-presant status and future potential[J ]. Clin Pharmacokinet,1994,26(1) :59.
  • 4Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21th century: does evidence support definitive outcomes? [J ]. Clin Pharmacokinet, 1998,34:265.
  • 5Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome[ J ]. Science ,2001,291 : 1304.
  • 6Cai WM, Chen B, Liu YX, et al. Dextromethorphan metabolic phenotyping in a native Chinese population[J ]. Acta Pharmacol Sin, 1997,18(5) :441.
  • 7Bertilsson L, Lou YQ,Du YL, et al. Pronounced differences between native Chinese and Swedish population in the polymorphic hydroxylation of debrisoquine and S-mephenytoin [ J ]. Clin Pharmacol Ther, 1992,51 : 388.
  • 8Ensom MHH,Chang TKH,Patel R. Pharmacogenetics- the therapeutic drug monitoring of the future? [ J ]. Clin Pharmacokinet ,2001,40(11) :783.
  • 9Chen S,Chou WH,Blouin RA,et al. The cytochrome P450 2D6(CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry [ J ]. Clin Pharmacol Ther,1996,60: 522.
  • 10Cai WM, Chen B, Zhou Y, et al. Fluoxetine impairs the metabolism of pmpafenone eanatiomers mediated by CYP2D6 in healthy Chinese volunteers[J]. Clin Pharmacol Ther, 1999,66(5):516.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部